United States

People: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

25 Oct 2016
Change (% chg)

$-0.12 (-1.75%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kishbauch, Michael 

Mr. Michael D. Kishbauch is Director of Achillion Pharmaceuticals Inc. From September 1996 to July 2004, Mr. Kishbauch was President and Chief Executive Officer of Achillion from July 2004 until his retirement in September 2013. From September 1996 to July 2004, Mr. Kishbauch founded and served as President and Chief Executive Officer of OraPharma, Inc., a publicly traded, commercial-stage pharmaceutical company focused on oral health care, which was acquired by Johnson & Johnson in 2003. Prior to OraPharma, Inc., Mr. Kishbauch held senior management positions with MedImmune, Inc., a biotechnology company. Mr. Kishbauch serves on the Board of Directors of Progenics Pharmaceuticals, Inc., an oncology company, and TetraLogic Pharmaceuticals, Inc, a biopharmaceutical company. Mr. Kishbauch holds a M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. Mr. Kishbauch has held senior management positions in the life sciences industry for over 28 years. His extensive operational, strategic and product planning and promotion experience is coupled with extensive sales, marketing and product launch experience. In addition, Mr. Kishbauch previously served as our Chief Executive Officer and has held board positions with several other life sciences companies.

Basic Compensation

Total Annual Compensation, USD 368,635
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 7,911
Fiscal Year Total, USD 376,546

Options Compensation

  Quantity Market Value
Exercisable 3,101,000 --
Unexercisable -- --
Exercised 297,415 2,762,190.00